Related Experiment Videos
Inhaled insulin: new technology, new possibilities
1Department of Medicine, University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK.
International Journal of Clinical Practice
|June 30, 2006
Summary
Inhaled insulin offers a new, effective alternative to traditional injections for managing type 1 and type 2 diabetes. Exubera, the first inhaled insulin, shows comparable efficacy and is now available in Europe and the USA.
Area of Science:
- Endocrinology
- Pharmacology
- Respiratory Medicine
Background:
- Diabetes mellitus prevalence is increasing globally, necessitating novel therapeutic strategies.
- Current diabetes management often relies on subcutaneous insulin injections, which can be burdensome for patients.
- Inhaled insulin represents a promising alternative drug delivery system for insulin therapy.
Purpose of the Study:
- To review the efficacy and safety profile of Exubera, an inhaled insulin product.
- To discuss the potential role of Exubera in the comprehensive management of diabetes mellitus.
Main Methods:
- Review of clinical trial data and regulatory submissions for Exubera.
- Comparative analysis of inhaled insulin efficacy against subcutaneous insulin.
- Assessment of safety data, including pulmonary function and adverse events.
Main Results:
- Exubera demonstrated comparable glycemic control to subcutaneous insulin in patients with type 1 and type 2 diabetes.
- The safety profile of Exubera was evaluated, with attention to pulmonary effects.
- Exubera has received regulatory approval in Europe and the USA.
Conclusions:
- Inhaled insulin, exemplified by Exubera, offers a viable alternative delivery method for insulin therapy.
- Exubera's efficacy and safety profile suggest a potential role in diabetes management, complementing existing treatments.
- Further research and clinical experience will define the long-term place of inhaled insulin in diabetes care.